RadNet Reports Third Quarter Financial Results with Record Quarterly Revenue and Adjusted EBITDA (1) and Revises Upwards 2025 Financial Guidance Ranges Total Company Revenue increased 13.4% to $522.

RadNet Reports Third Quarter Financial Results with Record Quarterly

Revenue and Adjusted EBITDA(1) and Revises Upwards 2025 Financial Guidance Ranges

LOS ANGELES, California, November 9, 2025 -

RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective outpatient diagnostic

imaging services and a premier global developer of digital health solutions, today reported financial results for its third quarter

Dr. Howard Berger, President and Chief Executive

Officer of RadNet, commented, "The business continues to demonstrate strong growth and record results in each of the Imaging Center

and Digital Health reportable operating segments. Total Company Revenue grew 13.4% and Adjusted EBITDA(1) grew 15.2% as compared

with last year's third quarter, resulting in Adjusted EBITDA(1) margin expansion of 26 basis points. Contributing to

the achievement of these results were the continued focus on creating capacity at existing centers, new center openings, ongoing business

mix shift towards advanced imaging, tuck-in acquisitions, increased reimbursement from commercial and capitated payors, the expansion

of health system joint ventures and an acceleration of Digital Health Revenue growth."

Dr. Berger continued, "During the quarter,

we experienced strong aggregate and same-center advanced imaging procedural volume growth. Aggregate advanced imaging procedural volumes

increased 13.0% and same-center advanced imaging grew 9.9% relative to last year's third quarter. As a result, RadNet's advanced

imaging business mix increased 153 basis points from last year's third quarter, from 26.7% of all procedures in the third quarter

of 2024 to 28.2% in the third quarter of 2025.

"Given the positive trends we are experiencing

in virtually all aspects of the business and the strong financial performance of the third quarter, we are revising upwards certain guidance

levels in anticipation of financial results that we believe will exceed both original expectations and the adjustments we made to the

guidance ranges upon releasing first and second quarter 2025 results. We have increased 2025 Imaging Center guidance ranges for Revenue

and Adjusted EBITDA(1) and have raised Revenue Guidance for the Digital Health operating segment," added Dr. Berger.

"RadNet's balance sheet remains strong.

At third quarter end, we had a cash balance of $804.7 million and a leverage ratio of Net Debt to Adjusted EBITDA(1) of approximately

1.0. This liquidity position provides the financial flexibility to continue to drive organic growth and to pursue attractive strategic

acquisitions of both imaging centers and digital health targets," concluded Dr. Berger.

Third Quarter Financial Results

For the third quarter of 2025, RadNet reported

Total Company Revenue of $522.9 million and Adjusted EBITDA(1) of $84.9 million. Revenue increased $61.7 million (or 13.4%)

and Adjusted EBITDA(1) increased $11.2 million (or 15.2%) as compared with the third quarter of 2024.

For the third quarter of 2025, RadNet reported

Digital Health Revenue (inclusive of intersegment revenue) of $24.8 million and Adjusted EBITDA(1) of $3.5 million. Revenue

increased $8.4 million (or 51.6%) and Adjusted EBITDA(1) increased $223,000 (or 6.9%) as compared with the third quarter of

Unadjusted for unusual or one-time items impacting

the third quarter, Total Company Net Income for the third quarter of 2025 was $5.4 million as compared with a Total Company Net Income

of $3.2 million for the third quarter of 2024. Fully diluted Net Income Per Share for the third quarter of

2025 was $0.07, compared with a fully diluted Net Income Per Share of $0.04 in the third quarter of 2024, based upon a weighted average

number of diluted shares outstanding of 77.4 million shares in 2025 and 75.2 million shares in 2024.

of unusual or one-time items impacting the third quarter including: $2.6 million of non-cash loss from interest rate swaps; $1.4

million in severance expense related to cost-savings initiatives; $621,000 expense related to leases for de novo facilities under construction

that have yet to open their operations; $5.5 million of non-capitalized research and development expenses related to the DeepHealth Cloud

OS and AI solutions; $2.1 million of acquisition transaction costs; and $2.8 million of lease abandonment charges. Adjusting for the above

items, Total Company Adjusted Earnings(3) was $15.8 million and diluted Adjusted Earnings Per Share(3) was $0.20

during the third quarter of 2025. This compares with Total Company Adjusted Earnings(3) of $13.3 million and diluted Adjusted

Earnings Per Share(3) of $0.18 during the third quarter of 2024.

For the third quarter of 2025, as compared with

the prior year's third quarter, MRI volume increased 14.8%, CT volume increased 9.4% and PET/CT volume increased 21.1%. Overall

volume, taking into account routine imaging exams, inclusive of x-ray, ultrasound, mammography and other exams, increased 6.9% over the

prior year's third quarter. On a same-center basis, including only those centers which were part of RadNet for both the third quarters

of 2025 and 2024, MRI volume increased 11.5%, CT volume increased 6.7% and PET/CT volume increased 14.9%. Overall same-center volume,

taking into account routine imaging exams, inclusive of x-ray, ultrasound, mammography and other exams, increased 4.9% over the prior

Nine Month Financial Results

For the first nine months of 2025, RadNet reported

Total Company Revenue of $1,492.5 million and Adjusted EBITDA(1) of $212.5 million. Revenue increased $139.9 million (or 10.3%)

and Adjusted EBITDA(1) increased $8.1 million (or 3.9%) as compared with the first nine months of 2024.

For the first nine months of 2025, RadNet reported

Digital Health Revenue (inclusive of intersegment revenue) of $64.8 million and Adjusted EBITDA(1) of $10.6 million. Revenue

increased $17.9 million (or 38.2%) and Adjusted EBITDA(1) increased $548,000 (or 5.5%) as compared with the first nine months

Unadjusted for one-time or unusual items, Total

Company Net Loss for the first nine months of 2025 was $18.1 million as compared with a Total Company Net Loss of $2.6 million for the

first nine months of 2024. Fully diluted Net Loss Per Share for the nine month period of 2025 was $(0.24),

compared with a Net Loss Per Share of $(0.04) in the nine month period of 2024, based upon a weighted average number of diluted shares

outstanding of 74.7 million shares in 2025 and 72.6 million shares in 2024.

2024 Guidance Update

RadNet amends its previously announced guidance

Imaging Center Segment

Digital Health Segment

Dr. Berger explained,

"Based upon the consistent outperformance of the first three quarters of this year relative to our projections, we have increased

guidance ranges of our core Imaging Center reporting segment for Revenue and Adjusted EBITDA(1).

With respect to the Digital Health reportable segment, we updated the Revenue guidance range upwards, due in part to the contribution

of iCAD Revenue beginning in mid-July. We have kept our Digital Health Adjusted EBITDA(1) guidance range unchanged."

Conference Call for Tomorrow

Dr. Howard Berger, President and Chief Executive

Officer, and Mark Stolper, Executive Vice President and Chief Financial Officer, will host a conference call to discuss its third quarter

2025 results on Monday, November 10th, 2025 at 7:30 a.m. Pacific Time (10:30 a.m. Eastern Time).

Conference Call Details:

Date: Monday, November 10, 2025

Time: 10:30 a.m. Eastern Time

Dial In-Number: 844-826-3035

International Dial-In Number: 412-317-5195

that participants dial in approximately 5 minutes prior to the start of the 10:30 a.m. call. There will also be simultaneous and archived

webcasts available at https://viavid.webcasts.com/starthere.jsp?ei=1740003&tp_key=5e6a1fc906 or

http://www.radnet.com under the "Investors" menu section and "News Releases" sub-menu of the website. An archived

replay of the call will also be available and can be accessed by dialing 844-512-2921 from the U.S., or 412-317-6671 for international

callers, and using the passcode 10204112.

RadNet, Inc. is a leading provider of outpatient

diagnostic imaging services in the United States, with a network of 407 owned and operated imaging centers. The company's markets

include Arizona, California, Delaware, Florida, Maryland, New Jersey, New York and Texas. In addition, RadNet provides radiology information

technology and artificial intelligence solutions marketed under the DeepHealth brand, teleradiology professional services and other related

products and services to customers in the diagnostic imaging industry. Together with contracted radiologists, and inclusive of full-time

and per diem employees and technologists, RadNet has over 11,000 team members. For more information, visit www.radnet.com.

Forward Looking Statements

This press release contains "forward-looking

statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking

statements are expressions of our current beliefs, expectations and assumptions regarding the future of our business, future plans and